Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2018 | Correction

Correction to: Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway

Authors: Bao-Xia Li, Heng-Bang Wang, Miao-Zhen Qiu, Qiu-Yun Luo, Han-Jie Yi, Xiang-Lei Yan, Wen-Tao Pan, Lu-Ping Yuan, Yu-Xin Zhang, Jian-Hua Xu, Lin Zhang, Da-Jun Yang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2018

Excerpt

In the publication of this article [1], there was an error in the Methods, Cell cultures and reagents section: the Methods, Cell cultures and reagents section: ‘The following primary antibodies were used: P62(#8025), phospho-H2AX(γ-H2AX;#9718), caspase-8(#9746), RIP1(#3493s), Beclin1(3738s), ATG7 (#2631S), PARP (#9546S), caspase-3(#9665s), cIAP1 (#7065s), cIAP2(3130s), XIAP(#14334), FADD(#2782S), phospho-NF-κBp105/p50(4806S), NF-κB2p100/p52(#4882S) and TNFR1(#3736S) were purchased from Cell Signaling Technology Inc.; GAPDH (#sc-47724) from Santa Cruz Biotechnology (SC); LC3 (#NB100–2220) from Novus Biologicals’. …

Li BX, Wang HB, Qiu MZ, et al. Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway. J Exp Clin Cancer Res. 2018;37:53. https://doi.org/10.1186/s13046-018-0703-9 CrossRefPubMedPubMedCentral

Title: Correction to: Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway
Authors: Bao-Xia Li
Heng-Bang Wang
Miao-Zhen Qiu
Qiu-Yun Luo
Han-Jie Yi
Xiang-Lei Yan
Wen-Tao Pan
Lu-Ping Yuan
Yu-Xin Zhang
Jian-Hua Xu
Lin Zhang
Da-Jun Yang
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2018
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-018-0774-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Downregulating CD26/DPPIV by apigenin modulates the interplay between Akt and Snail/Slug signaling to restrain metastasis of lung cancer with multiple EGFR statuses

Regulation of the adaptation to ER stress by KLF4 facilitates melanoma cell metastasis via upregulating NUCB2 expression

Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer

Distinct expression profiles and functions of Kindlins in breast cancer

Serum DNA integrity index as a potential molecular biomarker in endometrial cancer

MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence

Keynote webinar | Spotlight on antibody–drug conjugates in cancer